From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments

Last Updated: Wednesday, December 15, 2021

A small single-institution study found that immune responses to SARS-CoV-2 mRNA vaccines are induced for the majority of patients who have been treated with CAR T-cell therapies targeting B-cell lineage antigens.

JAMA Oncology
Advertisement
News & Literature Highlights

Journal of Medical Cases

Cyclophosphamide for the treatment of refractory immune effector cell-associated neurotoxicity syndrome following CD19-targeted CAR T-cell therapy

Transplantation and Cellular Therapy

Financial toxicity in a phase I/II trial of LV20.19 CAR-T cell for B-cell malignancies a longitudinal, qualitative study

Experimental Biology and Medicine

Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Frontiers in Immunology

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia

Blood

Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma

Mayo Clinic Proceedings. Innovations, Quality, & Outcomes

Operationalizing access for chimeric antigen receptor T cell therapies: A cross-functional perspective

World Journal of Oncology

Neurotoxicity of immunotherapy: Immune checkpoint inhibitor-related encephalitis vs. immune effector cell-associated neurotoxicity syndrome

Clinical and Translational Oncology

Emerging strategies to reduce the side effects of CAR-T cell therapy: Focusing on gene editing and nanotechnology

Transplantation and Cellular Therapy

Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies

Blood Advances

CAR T-cell toxicities: From bedside to bench, how novel toxicities inform laboratory investigations

Advertisement
Advertisement